ECSP066434A - Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos - Google Patents

Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos

Info

Publication number
ECSP066434A
ECSP066434A EC2006006434A ECSP066434A ECSP066434A EC SP066434 A ECSP066434 A EC SP066434A EC 2006006434 A EC2006006434 A EC 2006006434A EC SP066434 A ECSP066434 A EC SP066434A EC SP066434 A ECSP066434 A EC SP066434A
Authority
EC
Ecuador
Prior art keywords
acids
phenoxyacetics
phenoxialquil
uncle
analogs
Prior art date
Application number
EC2006006434A
Other languages
English (en)
Inventor
Gee-Hong Kuo
Rui Zhang
Aihua Wang
Alan R Deangelis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066434(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP066434A publication Critical patent/ECSP066434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a ácidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos, composiciones que los contienen y métodos de uso de los mismos como moduladores de PPAR delta para tratar o inhibir la progresión de, por ejemplo, dislipidemia.
EC2006006434A 2003-09-19 2006-03-17 Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos ECSP066434A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50414603P 2003-09-19 2003-09-19

Publications (1)

Publication Number Publication Date
ECSP066434A true ECSP066434A (es) 2006-09-18

Family

ID=34549183

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006434A ECSP066434A (es) 2003-09-19 2006-03-17 Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos

Country Status (29)

Country Link
US (9) US7301050B2 (es)
EP (2) EP2100877B1 (es)
JP (1) JP4928941B2 (es)
KR (1) KR101111475B1 (es)
CN (1) CN1882533B (es)
AR (1) AR045773A1 (es)
AT (1) ATE542793T1 (es)
AU (1) AU2004285849B2 (es)
BR (1) BRPI0414268B8 (es)
CA (1) CA2539446C (es)
CO (1) CO5680476A2 (es)
CR (1) CR8301A (es)
CY (1) CY1110555T1 (es)
DE (1) DE602004022179D1 (es)
DK (1) DK1667964T3 (es)
EA (1) EA012241B1 (es)
EC (1) ECSP066434A (es)
ES (2) ES2378435T3 (es)
IL (1) IL174398A (es)
NO (2) NO338511B1 (es)
NZ (1) NZ545943A (es)
PL (1) PL1667964T3 (es)
PT (1) PT1667964E (es)
SG (1) SG145752A1 (es)
SI (1) SI1667964T1 (es)
TW (1) TWI336238B (es)
UA (1) UA87467C2 (es)
WO (1) WO2005042478A2 (es)
ZA (1) ZA200603085B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1667964T1 (sl) * 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
BRPI0414534B8 (pt) * 2003-09-19 2021-05-25 Janssen Pharmaceutica Nv ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
KR20110091680A (ko) * 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
EP2870219B1 (en) * 2012-07-06 2016-05-25 Merck Patent GmbH Bimesogenic compounds and mesogenic media
EA201691039A1 (ru) 2013-11-20 2016-11-30 Саймабэй Терапьютикс, Инк. Лечение гомозиготной семейной гиперхолестеринемии
DK3119384T3 (en) * 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA121208C2 (uk) 2014-04-11 2020-04-27 Сімабей Терапьютікс, Інк. Лікування нажхп та насг
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
LT3973959T (lt) 2017-09-26 2025-01-10 Cymabay Therapeutics, Inc. Cholestazinio niežulio gydymas seladelparu
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
KR20210092754A (ko) 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021098885A1 (zh) * 2019-11-21 2021-05-27 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
SMT202400302T1 (it) 2021-02-01 2024-09-16 Cymabay Therapeutics Inc Trattamento di colangiopatie con seladelpar
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2026030479A1 (en) * 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Process for making seladelpar
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517051A (en) * 1964-03-20 1970-06-23 Merck & Co Inc Phenoxy substituted phenylacetic acids
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4109013A (en) * 1974-12-20 1978-08-22 Klinge Pharma Gmbh & Co. Substituted propanol-(2) derivatives of hydroxamic acids and the use thereof as hypolipemic drugs
US4125732A (en) 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) * 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
EP0106565B1 (en) 1982-09-30 1986-09-10 Merck Frosst Canada Inc. Leukotriene antagonists, their production, and compositions containing them
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) * 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
CA2244831A1 (en) * 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
ES2320181T3 (es) 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
EA200000687A1 (ru) * 1997-12-19 2000-12-25 Мерк Энд Ко., Инк. Производные арилтиазолидиндиона
CN1348439A (zh) 1999-04-20 2002-05-08 诺沃挪第克公司 新化合物及其制备和用途
ATE333448T1 (de) * 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0003310D0 (en) * 2000-02-15 2000-04-05 Univ Sheffield Bone formation
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
HUP0400280A3 (en) 2001-06-07 2006-01-30 Ligand Pharmaceuticals Inc San Modulators of peroxisome proliferator activated receptors, process for their preparation and pharmaceutical compositions containing them
BR0211414A (pt) * 2001-07-30 2004-08-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
IL160304A0 (en) 2001-08-10 2004-07-25 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta
PT1445258E (pt) 2001-10-12 2009-07-02 Nippon Chemiphar Co Activador para o receptor delta activado por proliferador de peroxissoma
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
JP4383177B2 (ja) * 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
BR0314335A (pt) 2002-09-05 2005-07-26 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
BR0315683A (pt) 2002-10-28 2005-08-30 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade
PL376704A1 (pl) 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR
CA2515481A1 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
US20060257987A1 (en) * 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
SI1667964T1 (sl) * 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
BRPI0414534B8 (pt) * 2003-09-19 2021-05-25 Janssen Pharmaceutica Nv ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os
KR20060109925A (ko) 2003-10-31 2006-10-23 얀센 파마슈티카 엔.브이. 퍼옥시좀 증식체-활성화된 수용체(ｐｐａｒ) 이중작용제로서 유용한 페녹시아세트산 유도체
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
BRPI0512951A (pt) 2004-07-01 2008-04-15 Hoffmann La Roche compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha)
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
HK1092784A1 (en) 2007-02-16
US20160199342A1 (en) 2016-07-14
ATE542793T1 (de) 2012-02-15
US20050124698A1 (en) 2005-06-09
DK1667964T3 (da) 2009-10-26
ZA200603085B (en) 2007-09-26
EA012241B1 (ru) 2009-08-28
IL174398A0 (en) 2006-08-01
AR045773A1 (es) 2005-11-09
CA2539446A1 (en) 2005-05-12
US20100069496A1 (en) 2010-03-18
NO338511B1 (no) 2016-08-29
US7301050B2 (en) 2007-11-27
BRPI0414268B1 (pt) 2017-04-04
DE602004022179D1 (de) 2009-09-03
CY1110555T1 (el) 2015-04-29
EA200600440A1 (ru) 2006-08-25
AU2004285849A1 (en) 2005-05-12
BRPI0414268B8 (pt) 2021-05-25
WO2005042478A2 (en) 2005-05-12
US20170304254A1 (en) 2017-10-26
UA87467C2 (en) 2009-07-27
US20190192475A1 (en) 2019-06-27
TWI336238B (en) 2011-01-21
US8518997B2 (en) 2013-08-27
NZ545943A (en) 2009-09-25
US20120122988A1 (en) 2012-05-17
US20080085927A1 (en) 2008-04-10
PL1667964T3 (pl) 2010-01-29
EP1667964A2 (en) 2006-06-14
CR8301A (es) 2008-11-24
EP2100877A1 (en) 2009-09-16
US7635718B2 (en) 2009-12-22
JP4928941B2 (ja) 2012-05-09
US9724322B2 (en) 2017-08-08
SG145752A1 (en) 2008-09-29
ES2378435T3 (es) 2012-04-12
NO20061728L (no) 2006-06-19
NO341448B1 (no) 2017-11-13
US20230210808A1 (en) 2023-07-06
NO20150447A1 (no) 2006-06-19
KR20070018804A (ko) 2007-02-14
HK1137737A1 (en) 2010-08-06
JP2007505916A (ja) 2007-03-15
CA2539446C (en) 2013-12-03
WO2005042478A3 (en) 2005-07-21
CO5680476A2 (es) 2006-09-29
CN1882533B (zh) 2010-06-09
TW200526561A (en) 2005-08-16
IL174398A (en) 2013-10-31
SI1667964T1 (sl) 2009-12-31
EP1667964B1 (en) 2009-07-22
US8106095B2 (en) 2012-01-31
KR101111475B1 (ko) 2012-03-15
BRPI0414268A (pt) 2006-11-07
US20130331453A1 (en) 2013-12-12
PT1667964E (pt) 2009-09-02
EP2100877B1 (en) 2012-01-25
AU2004285849B2 (en) 2011-04-28
ES2328581T3 (es) 2009-11-16
CN1882533A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
ECSP066434A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
ECSP077319A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos, y analogos de los mismos
ECSP077320A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
CR20220059A (es) Mezclas que comprenden plaguicidas de indazol
ECSP066536A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
BR0205767A (pt) Sais de sulfÈnio, composições curáveis por radiação, formulaçães lìquidas, e, método para a preparação dos sais de sulfÈnio
CR9507A (es) Sulfonamidas de diarisulfona y sus usos
ECSP066435A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
CL2004000256A1 (es) 2-cloro-n-(4'-clorobifenil-2-il)nicotinamida monociclica; procedimiento de preparacion; util para tratar hongos nocivos, su biotipo o las plantas, superficies, materiales o espacios para mantenerlos libres de ellos.
BR0013084A (pt) Heterociclil-2h-cromenos substituìdos
UY28512A1 (es) Difluoralquenos nematicidas
UY26684A1 (es) Compuestos fenilo sustituidos inhibidores de la farnesiltransferasa
DOP2003000733A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso